GTC Biotherapeutics (fka GTCB)

[shears]

The share price could not be propped up by token insider buying nor by the inanely expected positive HD trial data without the anticipated partnership coming to fruition. Bad calculations by GTCB's management. This backup plan for not signing a less than stellar partnership deal didn't work out as expected and many investors bailed IMO. Dilution occurred with a very low share price to begin with and now the management has lots of egg on its face and minimal cash. Too much egg and too little cash, IMO.

I will hold on to my shares but now my faith in management has been shaken so I will not buy any more 'cheap' shares. They will likely become cheaper as time goes on and GTCB's financial reserves dwindle. They let us believe the partnership was in the bag and nows its a nebulous affair, much too nebulous for this investor. The vultures and eels are circling whilst GTCB tries to keep its head above water.